Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands.
Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
Endoscopy. 2022 Mar;54(3):229-240. doi: 10.1055/a-1521-6318. Epub 2021 Jun 1.
Endoscopic eradication therapy with radiofrequency ablation (RFA) is effective in most patients with Barrett's esophagus (BE). However, some patients experience poor healing and/or poor squamous regeneration. We evaluated incidence and treatment outcomes of poor healing and poor squamous regeneration.
We included all patients treated with RFA for early BE neoplasia from a nationwide Dutch registry based on a joint treatment protocol. Poor healing (active inflammatory changes or visible ulcerations ≥ 3 months post-RFA), poor squamous regeneration (< 50 % squamous regeneration), and treatment success (complete eradication of BE [CE-BE]) were evaluated.
1386 patients (median BE C2M5) underwent RFA with baseline low grade dysplasia (27 %), high grade dysplasia (30 %), or early cancer (43 %). In 134 patients with poor healing (10 %), additional time and acid suppression resulted in complete esophageal healing, and 67/134 (50 %) had normal squamous regeneration with 97 % CE-BE. Overall, 74 patients had poor squamous regeneration (5 %). Compared with patients with normal regeneration, patients with poor squamous regeneration had a higher risk for treatment failure (64 % vs. 2 %, relative risk [RR] 27 [95 % confidence interval [CI] 18-40]) and progression to advanced disease (15 % vs. < 1 %, RR 30 [95 %CI 12-81]). Higher body mass index, longer BE segment, reflux esophagitis, and < 50 % squamous regeneration after baseline endoscopic resection were independently associated with poor squamous regeneration in multivariable logistic regression.
In half of the patients with poor healing, additional time and acid suppression led to normal squamous regeneration and excellent treatment outcomes. In patients with poor squamous regeneration, however, the risk for treatment failure and progression to advanced disease was significantly increased.
内镜下射频消融(RFA)根除治疗对大多数 Barrett 食管(BE)患者有效。然而,一些患者的愈合不良和/或鳞状上皮再生不良。我们评估了愈合不良和鳞状上皮再生不良的发生率和治疗结果。
我们纳入了一项全国性荷兰注册研究中根据联合治疗方案接受 RFA 治疗的早期 BE 肿瘤患者。评估了愈合不良(RFA 后≥3 个月仍有活动性炎症改变或可见溃疡)、鳞状上皮再生不良(<50%的鳞状上皮再生)和治疗成功(BE 完全根除[CE-BE])。
1386 例患者(中位 BE C2M5)接受了 RFA 治疗,基线时低级别上皮内瘤变(27%)、高级别上皮内瘤变(30%)或早期癌症(43%)。在 134 例愈合不良(10%)的患者中,额外的时间和酸抑制导致完全食管愈合,67/134(50%)的患者有正常的鳞状上皮再生,CE-BE 为 97%。总体而言,74 例患者的鳞状上皮再生不良(5%)。与正常再生的患者相比,鳞状上皮再生不良的患者治疗失败的风险更高(64%比 2%,相对风险[RR] 27[95%置信区间[CI] 18-40]),进展为晚期疾病的风险更高(15%比<1%,RR 30[95%CI 12-81])。多变量逻辑回归显示,较高的体重指数、较长的 BE 段、反流性食管炎和基线内镜切除后<50%的鳞状上皮再生与鳞状上皮再生不良独立相关。
在一半的愈合不良患者中,额外的时间和酸抑制可导致正常的鳞状上皮再生和良好的治疗效果。然而,在鳞状上皮再生不良的患者中,治疗失败和进展为晚期疾病的风险显著增加。